Notícias

We just covered the 10 Stocks That Will 10X According to Social Media. Sellas Life Sciences (NASDAQ:SLS) ranks #10 (see 5 Stocks That Will 10X According to Social Media). Number of Hedge Fund Investors: 13 Sellas Life Sciences (NASDAQ:SLS) is one of the top favorite stocks social media believes can 10x. It is a biotech […]

CEO Angelos Stergiou's equity award will vest over four years, increasing his ownership stake to 1.76 million shares.

Shareholders are set to vote on five proposals, including one to increase the number of shares available under the 2023 Equity Incentive Plan.

The United States market remained flat over the last week but has shown a strong performance with a 24% increase over the past year, and earnings are forecast to grow by 19% annually. In this context, identifying high growth tech stocks involves looking for companies that not only align with these optimistic earnings forecasts but also demonstrate robust innovation and adaptability in an ever-evolving industry landscape.

Sellas is seeking about $13 million in disputed GPS milestone payments related to Phase 3 development.

Sellas disclosed that it had 196.6 million shares of common stock outstanding as of June 2, 2026, according to an SEC filing.

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) was one of the stocks on Jim Cramer’s radar on Mad Money as he explained that many investors might be missing out on the market’s biggest winners. Responding to a caller’s question about the company, Cramer stated: Oh, this life science company that is, look, okay, so this is […]

In recent days, SELLAS Life Sciences Group drew attention as its CEO highlighted real-world data and prior Phase 2 results while the Phase 3 REGAL trial of GPS in AML moved to within two events of a topline readout. Investor interest was further amplified when CNBC’s Jim Cramer described SELLAS as “a great spec,” underscoring how imminent REGAL data and the progress of second AML candidate SLS009 are shaping perceptions of the company’s pipeline. We’ll now examine how the approaching REGAL...

CEO Angelos Stergiou said the trial's extended duration suggests patients are living longer than originally projected and said the company remains "very bullish."

Sellas believes GPS-treated AML patients could live longer than those receiving standard treatment, with a projected survival of about 12.6 months versus 8 months.

Sellas will participate Wednesday in TD Cowen’s Oncology Innovation Summit, marking the final major conference appearance ahead of the Regal data release.

The company plans to move quickly toward a pre-BLA meeting with the FDA and a potential filing if the REGAL trial reports positive results.

Retail speculation intensified as short interest in SLS climbed to a record high of 30.7% ahead of the final Regal catalyst.

Beyond leukemia, Sellas said GPS could potentially expand into up to 20 different tumor types.

Arm Holdings surged more than 15%, while Sellas Life Sciences rallied by over 18% and eBay climbed up 4% at close.

Earlier in 2026, SELLAS Life Sciences Group, Inc. reported a US$8.41 million net loss for the first quarter but narrowed its basic loss per share to US$0.05, while confirming that its pivotal Phase 3 REGAL trial in acute myeloid leukemia has reached 78 of the 80 events needed for final analysis. At the same time, SELLAS advanced its SLS009 program into an 80‑patient Phase 2 trial for newly diagnosed, high‑risk acute myeloid leukemia and secured additional funding flexibility through a...

Over the last 7 days, the United States market has remained flat, yet it is up 25% over the past year with earnings expected to grow by 17% annually in the coming years. In this context of robust growth and stability, identifying high-growth tech stocks involves focusing on companies that demonstrate strong innovation capabilities and adaptability to evolving market demands.

SELLAS Life Sciences Group Inc. (NASDAQ:SLS) reported first-quarter (Q1) 2026 financial results on Tuesday while highlighting progress across its acute myeloid leukemia (AML) pipeline. CEO Angelos Stergiou said the company continued advancing its clinical programs during the quarter while preparing for the anticipated data readout from its pivotal Phase 3 REGAL study. SELLAS will release the upcoming data after the study reaches its pre-specified 80th event threshold — a major milestone for the

Gainers Quantum Cyber (NASDAQ:QUCY) shares increased by 55.0% to $0.5 during Wednesday's pre-market session. The market value of their outstanding shares is at $4.0 million. SELLAS Life Sciences Gr (NASDAQ:SLS) shares increased by 21.26% to $6.33. The market value of their outstanding shares is at $963.2 million. The company's, Q1 earnings came out yesterday. Whitehawk Therapeutics (NASDAQ:WHWK) stock rose 20.17% to $4.71. The market value of their outstanding shares is at $193.8 million. As per

By Karen Roman Inventiva S.A. (Nasdaq: IVA) said Axel-Sven Malkomes joined the company as Chief Financial Officer, while Susan Coles and Pamela Herbster started their roles as Chief Legal Officer and Chief People Officer, respectively. The additions come as Inventiva prepares for potential commercialization from the Phase 3 trial of its MASH therapeutic, expected in […]

The mean of analysts' price targets for SELLAS Life Sciences Group, Inc. (SLS) points to a 66.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Sellas Life Sciences Group Inc. (NASDAQ:SLS) is one of the best healthcare penny stocks to buy according to hedge funds. On March 19, Chief Executive Officer Angelos Stergiou reiterated that 2026 is poised to be a pivotal year for Sellas Life Sciences Group Inc. (NASDAQ:SLS). The remarks align with the significant progress the company is […]

SELLAS Life Sciences Group Inc. (NASDAQ:SLS) is one of the popular penny stocks on Robinhood to buy. On March 17, SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) announced that it will present preclinical data on SLS009 at the American Association for Cancer Research annual meeting on April 21, 2026. SLS009, alternatively known as tambiciclib, is a […]

SELLAS Life Sciences Group, Inc. (SLS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The consensus price target hints at a 63.6% upside potential for SELLAS Life Sciences Group, Inc. (SLS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Assessing recent moves in SELLAS Life Sciences Group (SLS) SELLAS Life Sciences Group (SLS) has drawn attention after a recent run in its share price, with returns over the past 3 months and year that stand out against its mixed multi year track record. Over the past month the stock shows a gain, alongside a much stronger move in the past 3 months and a very large 1 year total return, while 5 year performance remains negative. That mix often prompts investors to revisit the story behind the...

A late-stage clinical biopharmaceutical company focused on immunotherapy for various cancers, SELLAS Life Sciences Group (NASDAQ:SLS) is at a genuinely unusual inflection point. Its shares have climbed 346% over the past year, yet the stock pulled back 13.4% in the past week to $5.04, with Q4 earnings due March 19. The reason Reddit is buzzing: ... SELLAS Stock Up 346% in a Year as Cancer Vaccine Trial Nears Its Final 8 Deaths

In late 2025, SELLAS Life Sciences Group reported encouraging Phase 2 data for SLS009 in combination with azacitidine and venetoclax in relapsed or refractory acute myeloid leukemia and confirmed that its Phase 3 REGAL trial of Galinpepimut-S would continue unchanged after an Independent Data Monitoring Committee review. Taken together, these developments highlight both near-term clinical momentum around SLS009 and growing validation of Galinpepimut-S as a potential maintenance therapy in...

SELLAS Life Sciences Group (SLS) is back in focus after encouraging clinical updates on its leukemia programs, including Phase 2 data for SLS009 and ongoing progress in the Phase 3 REGAL trial for Galinpepimut S. See our latest analysis for SELLAS Life Sciences Group. The recent clinical updates appear to be reflected in momentum, with a 44.8% 1 month share price return, a 217.8% 3 month share price return and a very large 1 year total shareholder return, although the 5 year total shareholder...